EVAX Stock Analysis: Buy, Sell, or Hold?
EVAX - Evaxion A/S American Depositary Share
$2.96
-0.23 (-7.21%)
▼
5d:
-16.62%
30d:
-38.34%
90d:
-48.7%
WAIT
LOW Confidence
Analysis Updated: Feb 4, 2026 12:00 AM ET
Get Alerted When EVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EVAX is down 16.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EVAX is down 16.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: EVAX is currently trading at $2.96, which is considered oversold relative to its 30-day fair value range of $3.64 to $5.11.
Technical Outlook: Technically, EVAX is showing sideways momentum. The price is currently testing key support at $2.91. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.33 (+286.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EVAX is showing sideways momentum. The price is currently testing key support at $2.91. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.33 (+286.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$3.64 -
$5.11
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.2%)
- BULLISH: Trading 286.6% below Wall St target ($12.33)
- WARNING: Recommendation downgraded due to -16.6% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$3.64 -
$5.11
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$2.91
Resistance Level
$4.48
Current Trend
Sideways
Technical data as of
Feb 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-212.67
Wall Street Target
$12.33
(+286.6%)
Revenue Growth (YoY)
148.3%
Profit Margin
-70.8%
Last updated: February 04, 2026 2:27 PM ET
Data refreshes hourly during market hours. Next update: 3:27 PM
Data refreshes hourly during market hours. Next update: 3:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 66 BUY |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 52 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 64 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$140 | 53 HOLD |